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Abstract
Multidrug-resistant Acinetobacter baumannii (MDRAB) is an increasing problem worldwide. Prevalence of carbapenem
resistance in Acinetobacter spp. due to acquired carbapenemase genes is not known in Finland. The purpose of this study
was to examine prevalence and clonal spread of multiresistant A. baumannii group species, and their carbapenemase genes.
A total of 55 Acinetobacter isolates were evaluated with repetitive PCR (DiversiLab) to analyse clonality of isolates, in
conjunction with antimicrobial susceptibility profile for ampicillin/sulbactam, colistin, imipenem, meropenem, rifampicin
and tigecycline. In addition, a new real-time PCR assay, detecting most clinically important carbapenemase genes just in two
multiplex reactions, was developed. The assay detects genes for KPC, VIM, IMP, GES-1/-10, OXA-48, NDM, GIM-1, SPM-1, IMI/
NMC-A, SME, CMY-10, SFC-1, SIM-1, OXA-23-like, OXA-24/40-like, OXA-58 and ISAbaI-OXA-51-like junction, and allows
confident detection of isolates harbouring acquired carbapenemase genes. There was a time-dependent, clonal spread of
multiresistant A. baumannii strongly correlating with carbapenamase gene profile, at least in this geographically restricted
study material. The new carbapenemase screening assay was able to detect all the genes correctly suggesting it might be
suitable for epidemiologic screening purposes in clinical laboratories.
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Introduction
Acinetobacter baumannii is a hospital-acquired pathogen which
commonly causes pneumonia, bloodstream infections, meningitis,
wound infections and urinary tract infections, especially in patients
with impaired host defences. A. baumannii isolates are resistant to
many antimicrobial classes: fluoroqinolones, tetracyclines, cepha-
losporines and aminoglycosides [1]. However, today carbapenem
resistance is more frequently encountered [1–3]. In A. baumannii
carbapenem resistance is usually conferred by carbapenem-
hydrolyzing class D oxacillinases (CHDLs), including OXA-23-
like (blaOXA-23-like), OXA-40-like (blaOXA-40-like), OXA-58-like
(blaOXA-58-like), and OXA-143-like (blaOXA-143-like) oxacillinases. Ad-
ditionally A. baumannii has the intrinsic OXA-51-like (blaOXA-51-like)
oxacillinase [4,5]. Although CHDLs exhibit weak carbapenem
hydrolysis, they can confer resistance when overexpressed. This
resistance is mediated through a combination of naturally low
permeability to b-lactams, efflux pumps and ISAba elements located
upstream of the gene, providing a strong promoter activity [6]. In
addition, A. baumannii may harbour many other carbapenemases
more commonly found among Enterobacteriaceae and Pseudomonas
species [7].
To determine genetic and epidemiological relatedness, genomic
fingerprinting of clinical isolates is required. One of the most
effective method is the repetitive extragenic palindromic sequence-
based polymerase chain reaction (rep-PCR), which is commer-
cially available known as the DiversiLab microbial typing system
(bioMe´rieux, Marcy L’Etoile, France) [8]. This system has been
proven useful in the typing of A. baumannii and has demonstrated
good discriminatory ability, comparable with pulsed-field gel
electroproresis (PFGE) and multilocus sequence typing (MLST)
[9,10]. Recently this rep-PCR typing system, DiversiLab, has
identified eight carbapenem-resistant A. baumannii clonal lineages
(WW1 to WW8) that are distributed worldwide [4]. DiversiLab
fingerprints between laboratories were recently tested and
clustering was found to be conserved [11].
The carbapenem resistance has recently attracted new interest
as a subset among tens of gene families has spread to
Enterobacteriaceae [12–14], despite a much longer history among
Pseudomonas and Acinetobacter species. A. baumannii may harbour
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most of the acquired carbapenemase genes within Enterobacteriaceae,
and Pseudomonas in addition to their characteristics CDHL genes
[7].
Recently, new molecular assays have been described to detect
most prevalent carbapenemase genes [15], or a subset of A.
baumannii selective carbapenemase genes. Due to limited gene set,
or technical limitations, most new tests are not suitable for clinical
routine monitoring in low prevalence settings [16]. In addition,
combinations of other resistance mechanisms, such as reduced
permeability due porin mutations, or defect, and efflux pumps in
conjunction with ampC b-lactamases are the most common cause
of carbapenem resistance in low prevalence areas [14]. Therefore,
an imipenem hydrolysis test or dedicated MALDI-TOF [17] and
more extensive screening of resistance mechanisms in a reference
laboratory are often needed to reliably exclude carbapenemase
genes.
The aim of this study was to investigate the carbapenemase
genes of A. baumannii and the correlation between these genes and
clonal lineages. The feasibility of a new real-time PCR assay was
tested for screening of most important carbapenemase genes
detected among A. baumannii, Enterobacteriaceae, and Pseudomonas
species.
Materials and Methods
Bacterial strains and culture conditions
A total of 55 Acinetobacter isolates from 44 patients were detected.
51 isolates with reduced susceptibility to carbapenem from
HUSLAB (Laboratory of Helsinki University Central Hospital)
between Jun 18th 1993 and Jan 18th 2008 were collected and four
Acinetobacter isolates suscebtible to carbapenems were included as
controls. Helsinki University Hospital is responsible for the
secondary and tertiary care of app. 1.5 million people. The
culture samples from this area received by HUSLAB are both
from these hospitals as well as from outpatients of this geographical
area, the Helsinki and Uusimaa district in southern Finland. The
culture samples in this study were from patients treated in nine
different hospitals (Table S1).
Acinetobacter isolates were cultured in aerobic atmosphere on
chocolate and cysteine lactose electrolyte deficient (CLED) agar
and incubated at 35uC for 18 h. Colonies with typical morphology
and biochemistry were identified as A. baumannii complex.
Identification with the VITEK 2 (bioMe´rieux, Marcy L’Etoile,
France) system with GN card was performed, as well. 16S rRNA
gene sequencing was performed when biochemical identification
was equivocal. In addition a house-keeping OXA-51-like
(blaOXA-51-like) gene was detected separately within all the clinical
isolates with reduced susceptibility to carbapenems, whereas
carbapenem susceptible control strains did not harbour OXA-
51-like genes.
Antimicrobial susceptibility testing was performed by the disk
diffusion method according to the CLSI guidelines (http://www.
clsi.org). MICs for ampicillin/sulbactam, colistin, imipenem,
meropenem, rifampicin and tigecycline by E-test (AB BIODISC,
Solna, Sweden) were determined on Mueller-Hinton agar
according to manufacturer’s instructions.
Design of multiplex Real-Time carbapenemase gene
screening assay
The assay was designed to detect most clinically relevant
carbapenemase genes described within A. baumannii, Pseudomonas
aeruginosa, and Enterobacteriaceae species. The design was performed
using AlleleID software (http://www.premierbiosoft.com), taking
into account all the globally known sub-variants in NCBI data
base. For practical purposes, the assay was divided in two
multiplex reactions consisting of nine and eight gene families,
respectively. The assay was validated in vitro using 43 positive
Table 1. Description of validation isolates.
Target Species Isolation site Travel history
GES-1 P. aeruginosa wound no
GES-14 K. pneumoniae trachea n/a
GES-5 P. aeruginosa incision wound no
GES-5 P. aeruginosa incision wound no
IMI-1 E. cloacae stool Thailand
IMI-2 E.cloacae wound no
IMP-15 P. aeruginosa blood no
IMP-15 P. aeruginosa wound no
IMP-15 P. aeruginosa incision wound no
IMP-15 P. aeruginosa urine no
IMP-15 P. aeruginosa urine n/a
IMP-15 P. aeruginosa incision wound n/a
IMP-15 P. aeruginosa urine n/a
ISAbaI-OXA-51 A. baumannii stool Spain
ISAbaI-OXA-51 A. baumannii stool no
ISAbaI-OXA-51 A. baumannii trachea no
KPC K. pneumoniae stool US
KPC-2 K. pneumoniae stool Greece
KPC-2 K. pneumoniae wound Italy
KPC-2 K. pneumoniae urine no
KPC-2 K. pneumoniae blood Mexico/US
KPC-2 K. pneumoniae urine no
NDM-1 K. pneumoniae stool n/a
OXA-23 A. baumannii blood n/a
OXA-23 A. baumannii wound no
OXA-23 A. baumannii trachea Thailand
OXA-48 E. coli stool Syria
OXA-48 K. pneumoniae stool Turkey
OXA-48 A. baumannii stool n/a
OXA-58 A. baumannii stool Tunis
OXA-58 A. baumannii wound no
OXA-58 A. baumannii wound no
OXA-58 A. baumannii stool Greece
OXA-58 A. baumannii incision wound n/a
OXA-58 A. baumannii urine no
SFC-1 S. fonticola control strain Portugal
SIM-1 A. baumannii control strain South-Korea
SME S. marcescens control strain n/a
VIM P. aeruginosa stool Thailand
VIM K. pneumoniae stool Spain
VIM K. pneumoniae stool Greece
VIM K. pneumoniae CV cathether n/a
VIM-1 K. pneumoniae blood Greece
VIM-2 P. aeruginosa trachea Russia
VIM-2 P. aeruginosa trachea Russia
doi:10.1371/journal.pone.0085854.t001
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control strains (Table 1), which were confirmed at National
Institute for Health and Welfare, Turku, Finland [14]. Since the
target primer regions were fully conserved in silico, it was
considered adequate to demonstrate PCR performance with one
or more control species representing all the gene variants. In
addition, synthetic gene constructs for SFC, CMY-1/10, SIM,
SME, OXA-25, and OXA-58 genes containing a partial, non-
functional resistance gene in E. coli plasmid (pIDTsmart), including
the amplicon and app. 20 bp upstream and downstream sequence
(Integrated DNA Technologies Inc, CA, USA). The plasmid was
then transfected into the TOP10 strain according to manufactur-
er’s instructions. The construct was ordered from IDT using
pSMART plasmid, blunt-ended, containing a kanamycin resis-
tance gene. The SFC, and SIM the control strains were obtained
later (as a kind gift from Dr. Correia and Dr. Yunsop Chong and
Kyungwon Lee, consequently). All the gene products were
confirmed by sequencing with reference primers, or the gene
Table 2. Primers used for amplification of resistance genes by
polymerase chain reaction (PCR).
Primer Sequence 59- 39 Reference Oligomix
F_ges_001 ACACCTGGCGACC-
TCAGAGATAC
This study 1
R_ges_001 ACTTGACCGACA-
GAGGCAACTAATTC
This study 1
F_gim_001 CGAATGGGTTGGTAG-
TTCTGGATAATAATC
This study 1
R_gim_001 ATGTGTATGTAGG-
AATTGACTTTGA-
ATTTAGC
This study 1
F_imi1_001 AAACAAGGGAA-
TGGGTGGAGACTG
This study 1
R_imi1_001 AAGGTATGCTTT-
GAATTTGCGTTG
This study 1
F_imp_10 AATAATGACGCCT-
ATCTAATTGACACTCC
This study 1
R_imp_10 ATTCCACCCGTA-
CTGTCGCTATG
This study 1
F_imp_11 TGACGCCTATCTG-
ATTGACACTCC
This study 1
R_imp_11 GCTGTCGCTATGG-
AAATGTGAGG
This study 1
F_kpc_001 CAGCGGCAGCAG-
TTTGTTGATTG
This study 1
R_kpc_001 CCAGACGACGGC-
ATAGTCATTTG
This study 1
F_oxa48_003 TTACTGAACATAA-
ATCACAGGGCGTAG
This study 1
R_oxa48_003 ATTATTCGTAAATC-
CTTGCTGCTTATTCTC
This study 1
F_sme_006 CAGATGAGCGGTT-
CCCTTTATGC
This study 1
R_sme_006 CAGAAGCCATA-
TCACCTAATGTCATACC
This study 1
F_spm_001 CCTACAATCTAA-
CGGCGACCAAG
This study 1
R_spm_001 AACGGCGAAGA-
GACAATGACAAC
This study 1
F_vim_03 GTGTTTGGTCGCA-
TATCGCAAC
This study 1
R_vim_03 GCTGTATCAATC-
AAAAGCAACTCATC
This study 1
F_cmy_01 CAGGTGCTCTTC-
AACAAG
This study 2
R_cmy_01 CGCCCTCTTTCTTTCAAC This study 2
F_IS51_01 GTCATAGTATT-
CGTCGTTAGA
This study 2
R_IS51_01 GTAAGAGTGCTTTAATG-
TTCATA
This study 2
F_ndm_01 CGATCAAACCGTTGGAAG This study 2
R_ndm_01 AAGGAAAACTTGATG-
GAATTG
This study 2
F_oxa24_02 ACTTTAGGTGAGGCAATG This study 2
R_oxa24_02 TAACTTCTTGTA-
CTGGTGTAA
This study 2
F_oxa27_001 ATATTTTACTTGCTATG-
TGGTTGCTTCTC
This study 2
R_oxa27_001 TCTCCAATCCGATC-
AGGGCATTC
This study 2
Table 2. Cont.
Primer Sequence 59- 39 Reference Oligomix
F_oxa58_02 GACAATTACACCTA-
TACAAGAAG
This study 2
R_oxa58_02 CGCTCTACATAC-
AACATCTC
This study 2
F_sfc_01 CCTGGTGATGAT-
AGAGATAC
This study 2
R_sfc_01 ATAATCGTTGGCTGTACC This study 2
F_sim_01
CTGCTGGGATAGAGTGGCTTAATACThis
study2R_sim_01TCAATAGTGATGCGTCTCCGATTTCThis study2
doi:10.1371/journal.pone.0085854.t002
Table 3. Control strains.
Gene Bacterium
Ct (50
ng/ml) T(m)
PCR
reaction
GES-1 K. pneumoniae 23 84 PCR1
GIM-1 P. aeruginosa 16 80 PCR1
IMI-2 E. cloacae 14 78 PCR1
IMP-15 P. aeruginosa 15 77 PCR1
KPC-2 K. pneumoniae 17 87 PCR1
OXA-48 E. coli 15 75 PCR1
SME S. marcescens 11 77 PCR1
SPM-1 P. aeruginosa 16 80 PCR1
VIM-1 K. pneumoniae 17 81 PCR1
CMY-1/10 E.coli* 16 88 PCR2
ISaba1-OXA-51- family Acinetob. spp 19 72 PCR2
NDM-1 K. pneumoniae 18 87 PCR2
OXA-23- family Acinetob. spp 22 78 PCR2
OXA-24/40- family Acinetob. spp 17 79 PCR2
OXA-58 E.coli* 15 76 PCR2
SFC-1 E.coli* 16 81 PCR2
SIM-1 Acinetob. spp 21 80 PCR2
* = gene construct containing the partial, non-functional resistance gene in E.
coli plasmid.
doi:10.1371/journal.pone.0085854.t003
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specific primers alone, when published reference primers were not
available. For additional species identification, OXA-51 gene
(blaOXA-51-like), with or without ISAbaI, was detected separately,
using F_oxa51_001 AATTTATTTAACGAAGCACACAC-
TACGG, and R_oxa51_001 GCACGAGCAAGATCATTAC-
CATAGC primers and the PCR program shown below.
The specificity was tested with 58 carbapenem susceptible
Enterobacteriaceae isolates (Table S2) [18], and 710 isolates with
putative reduced susceptibility A. baumannii, P. aeruginosa and
Enterobacteriaceae isolated from clinical samples during 2008–2011.
These isolates were selected among samples growing on
CHROMagar ESBL, or CHROMagar KPC plates (bioMe´rieux,
Marcy L’Etoile, France), or from other culture isolates with disk
diffusion diameter ,25 mm for ertapenem, or ,22 mm for
meropenem, or MIC.0,5 mg/l for ertapenem and meropenem.
Validation of multiplex Real-Time PCR assay
Template DNA was extracted from a single colony on CLED
plate grown overnight, and re-suspended in 100 ml TE-buffer
(0,5 McF) and boiled 15 min. Each 20 ml real time PCR-reaction
included 10 ml Maxima SYBR Green qPCR Master Mix (2X)
(Scientific Fermentas, Schwerte, Germany), 6 ml Oligomix 1 or 2
(Table 2), IDT (Integrated DNA Technologies, Inc.), 3 ml H20,
and 1 ml DNA template. Amplification was performed as follows:
95uC 10 min initial denaturation, 30 cycles with 95uC 20 sec
denaturation, 58uC 30 sec annealing and extension, final exten-
sion 58uC 1 min and final denaturation 95uC 30 sec (MxPro
Table 4. Primers used for sequencing of resistance genes by polymerase chain reaction (PCR).
Gene Primer Sequence (59- 39) Size (bp) T (m) Reference
CMY F_cmy_s1 TAAGATACTTCGGATGAGGAG 695 60
R_cmy_s1 GCATCTTCTCGGATGAATC This study
GES-C GTTTTGCAATGTGCTCAACG 371 60
GES GES-D TGCCATAGCAATAGGCGTAG [25]
GIM-1F AGAACCTTGACCGAACGCAG 748 60
GIM GIM-1R ACTCATGACTCCTCACGAGG [25]
IMI-A ATAGCCATCCTTGTTTAGCTC 818 55
IMI IMI-B TCTGCGATTACTTTATCCTC [25]
F_IMP-1 TGAGCAAGTTATCTGTATTC 740 55
IMP R_IMP-1 TTAGTTGCTTGGTTTTGATG [25]
F_IMP-2 GGCAGTCGCCCTAAAACAAA 737 55
IMP R_IMP-2 TAGTTACTTGGCTGTGATGG [25]
ISaba1/OXA-51 F_IS51_01 GTCATAGTATTCGTCGTTAGA 301 60
R_oxa51_001 GCACGAGCAAGATCATTACCATAGC This study
F_KPC ATGTCACTGTATCGCCGTCT 893 55
KPC R_KPC TTTTCAGAGCCTTACTGCCC [25]
NDM F_ndm_s1 GACAACGCATTGGCATAAG 447 60
R_ndm_s1 AAAGGAAAACTTGATGGAATTG This study
OXA-23 family F_oxa23_s1 GTGTCATAGTATTCGTCGTTAG 592 60
R_oxa23_s1 TATCAACCTGCTGTCCAAT This study
OXA-24 family F_oxa25_s1 ATTAGGGCTTGAGTGGAAA 521 60
R_oxa25_s1 TTGTATGATTGTCAACTGCTAT This study
OXA-48A TTGGTGGCATCGATTATCGG 744 62
OXA-48 OXA-48B GAGCACTTCTTTTGTGATGGC [25]
SFC F_sfc_s1 CTCATTCTCCTGTGACTGA 351 60
R_sfc_s1 TTGCTCCTCCTGTTGTATT This study
SIM1-F TACAAGGGATTCGGCATCG 571 60
SIM SIM1-R TAATGGCCTGTTCCCATGTG [25]
F_sme_s1 AAGGCTCAGGTATGACATT 410 60
SME R_sme_s1 GGCATAATCATTCGCAGTA This study
SPM-1F CCTACAATCTAACGGCGACC 650 55
SPM SPM-1R TCGCCGTGTCCAGGTATAAC [25]
F_VIM-1 TTATGGAGCAGCAACCGATGT 920 60
VIM R_VIM-1 CAAAAGTCCCGCTCCAACGA [25]
F_VIM-2 AAAGTTATGCCGCACTCACC 865 60
VIM R_VIM-2 TGCAACTTCATGTTATGCCG [25]
doi:10.1371/journal.pone.0085854.t004
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3005P, Stratagene, La Jolla, CA, USA). Melting curve was
determined between temperatures 58–95uC. Control strains are
presented in Table 3.
The PCR was run as a preformed oligonucleotide mixture with
master mixture and template to avoid quality variations between
the runs. A new oligonucleotide mixture was always tested with all
the panel targets with set expected 19–25 Cq range in qPCR
depending on the target (Table 3). The oligonucleotide mixture
was stored in stock concentrations in small aliquots, and a working
dilution was formed for short term usage only. In addition, each
PCR run including a representative negative and positive control
for the given multiplex: KPC for multiplex 1 and NDM for
multiplex 2. An acceptance range for positive controls (target +/2
3 Cq) was implemented to accept test series.
All positive isolates were confirmed by further analysing by an
independent, conventional PCR and by sequencing the carbape-
nemase gene. Primers used in sequencing are presented in Table 4.
Reaction included 2,5 mM dNTP 1,6 ml, HotStarTaq polymerase
(Qiagen, Helsinki, Finland), 0,1 ml, Polymerase Buffer 1062 ml,
primer F and R 1 ml each, H20 13,3 ml and 1 ml template making a
total of 20 ml reaction volume. Amplification was performed as
follows: initial denaturation 95uC 15 min, 35 cycles with
denaturation 94uC 30 sec, variable annealing temperature 55/
60/62uC 30 sec depending on the carbapenemase gene to be
amplified, extension 72uC 10 min, final extension 72uC 10 min
(DNA Engine Tetrad 2, Peltier Thermal Cycler, BioRad, CA,
USA).
Rep-PCR
DNA was extracted from colonies on CLED plates using the
UltraClean microbial DNA isolation kit (Mo Bio Laboratories,
Solona Beach, CA, USA) and diluted to 35 ng/ml. The DNA was
amplified using the DiversiLab Acinetobacter kit (Bacterial Barcodes,
Inc. cat no DL-AB01, Athens, GA, USA) for DNA fingerprinting
following the manufacturer’s instructions. PCR was run on
preheated thermal cycler (DNA Engine Tetrad 2, Peltier Thermal
Cycler BioRad, Hercules, CA, USA) using the parameters
according to manufacturer’s recommendations. The kit specific
positive and negative controls were run with each reaction set for
the validation of amplification. The rep-PCR products were
detected and the amplicons were separated using microfluidics lab-
on-a-chip technology and analysed using the DiversiLab system
(Bacterial Barcodes, Inc.). Further analysis was performed with the
web-based DiversiLab software (version 3.4) using the band-based
modified Kullback-Leibler distance for the calculation of percent
similarities. The manufacturer provides guidelines for strain-level
discrimination; similarity more than 97% is considered as
indistinguishable (no differences in fingerprints), similarity more
than 95% as similar (1-2 band difference in fingerprints) and
similarity less than 95% as different. In this study optimal cut-off
for clustering was 95%.
Ethics statement
The bacterial isolates analyzed in this study belong to the
microbiological collections of HUSLAB (Laboratory of Helsinki
University Central Hospital) and were obtained as part of routine
clinical care in the past. Furthermore, all patient identifiers had
been previously removed and data were analyzed anonymously.
As the isolates were not clinical samples in the legal sense, no
written or verbal consent was needed.
Figure 1. DiversiLab analysis. Dendogram and computer-generated
image of rep-PCR banding patterns showing clustering between
oxacillinase genes; OXA-23-like, OXA-24-like and OXA-58.
doi:10.1371/journal.pone.0085854.g001
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Results
Characterization of carbapenemase genes with A.
baumannii
All the strains were analysed for 17 carbapenemase gene groups
using the new assay. Among these A. baumannii isolates the most
prevalent gene was OXA-23-like (blaOXA-23-like). In addition we
also found eight OXA 58 (blaOXA-58) genes and one OXA-24-like
(blaOXA-24-like) gene (Figure 1). No other carbapenemase genes,
including genes for KPC, VIM, IMP, GES-1/-10, OXA-48,
NDM, GIM-1, SPM-1, IMI/NMC-A, SME, CMY-10, SFC-1,
and SIM-1, were detected. The ISAbaI-OXA-51-like junction
PCR was negative in all strains, as well (data not shown).
Temporal variation of prevalent, endemic A. baumannii
clones
A time dependent clonal variation among the analysed A.
baumannii was observed. A predominant clone was detected during
the follow-up period, typically lasting a few years, which was then
substituted by a new clone (Figure 2). Briefly, first a few isolates,
harbouring a mobile element with OXA-58 gene, appeared 1993–
1996 and 2003–2006 (Clone 1, Figure 1), which was not detected
in the following years, followed by a clone harbouring a mobile
OXA-23-like gene (Clone 2, Figure 1). The results were consistent
with DiversiLab typing, and characteristic antibiotic susceptibility
profile associated with the OXA clones analyzed. Only five out of
55 species having OXA-23/-58 gene displayed a different rep-
PCR profile. Based on rep-PCR analysis, two predominant clones
were detected. One isolate having OXA-24-like gene was unique
in DiversiLab analysis, as well. As expected, all the control isolates
from patient with no known connection were unique in their rep-
PCR profiles.
Association of antibiotic susceptibility with clonality and
carbapenemase gene profile
In our study, OXA-58 isolates had lower MIC-values for to
meropenem than OXA-23-like positive isolates that systematically
had higher MIC-values (Table 5). The isolates with non-acquired
OXA-gene, displayed a marked variation and they included also
some carbapenem resistant isolates. The control isolates (Figure 1)
consisted of Acinetobacter spp not harbouring any of the OXA genes
analyzed. These isolates were all carbapenem susceptible (Table 5).
Discussion
The carbapenemase producing multi-resistant gram negative
rods are probably the most important challenge for hospital
hygiene at the moment [13,19]. The great variety of underlying
mechanisms, in contrast to simple mecA or mecC in MRSA,
possesses a significant challenge to clinical screening process.
Phenotypes are highly variable and many overlapping other
resistance mechanisms complicate any simple screening approach.
A straight-forward, economical method suitable for routine clinical
diagnostics has not been available yet. In this paper we
demonstrate the good performance of a new multiplex real-time
PCR assay, detecting most important carbapenemases based on
melting curve analysis, by applying it to an epidemiologically
important set of clinical A. baumannii isolates. In a striking contrast
to carbapenemase producing Enterobacteriaceae, which were first
detected in Finland 2008 [14], the carbapenem resistant A.
baumannii were detected in Finland already three decades ago. This
study highlights the emergence of carbapenem-resistant A.
baumannii isolates carrying the blaOXA-23-like gene (Clone 1), which
replaced the blaOXA-58 gene (Clone 2) in three years (Figure 2).
These major clones might have been endemic.
The new carbapenemase detection assay was initially developed
to detect carbapenemase producing Enterobacteriaceae isolates, but it
also appeared to be a useful tool for P. aeruginosa and A. baumannii.
After three years of clinical use, it has been proved to be sensitive
and highly specific screening assay among more than 700 hundred
Figure 2. Time-dependent distribution of acquired oxacillinase genes; OXA-23-like, OXA-24-like and OXA-58.
doi:10.1371/journal.pone.0085854.g002
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isolates with reduced carbapenem susceptibility analysed to date
[14]. One of the major problems related to molecular detection of
many antibiotic resistance genes is the appearance of new genomic
variants. For example, the variable regions of blaOXA-181 are up to
9% different from blaOXA-48 [20]. The new variants may not be
detectable with the existing systems. To minimize the risk for false
negative results, the primers were designed at conserved gene
regions to achieve optimal amplification of all the current and
forthcoming sub-variants. The SYBR Green chemistry was
preferred to avoid false negative results due to minor mutations
in the probe sequence. The probe based assays are often sensitive
to just 1–2 mutations in probe sequence, whereas primers are
usually less sensitive to minor target mutations. These design
features were considered relevant to achieve a high exclusion
power of clinically relevant, acquired carbapenemase genes among
carbapenem resistant strains.
A. baumannii is a nosocomial pathogen, and epidemiological tools
are important to develop effective strategies for better monitoring
of MDRAB clinical isolates [21]. In this study we used rep-PCR
because the method is suitable for comparison of isolate genetic
profiles using standardized and automated format [22]. This
method has previously demonstrated good discrimination ability of
A. baumannii isolates [23,24]. We found two major clones with
DiversiLab (Clone 1 and 2, Figure 1.) harbouring most of the
isolates with blaOXA-23-like and blaOXA-58 genes. There were only
few exceptions. The cases were mostly from departments of
treating patients with severe burn trauma, or intensive care units.
In this study, a good correlation between the carbapenemase
gene and DiversiLab typing suggested that they both could be
effectively applied for epidemiological screening of A. baumannii
species. The new carbapenemase gene screening assay has been in
clinical use for more than three years, and it has been a highly
suitable method for rapid unequivocal identification of isolates
harbouring acquired carbapenemase genes among Acinetobacter,
Pseudomonas aeruginosa, and Enterobacteriaceae species. This study
suggests that the new molecular methods could be successfully
applied in clinical diagnostics to monitor acquired carbapenemase
genes, provided that they are user-friendly and cost-effective as well.
Table 5. MIC distributions for 55 Acinetobacter isolates.
Cumulative percentage of isolates inhibited at MIC (mg/l) value of:
Drug #0.5 #1 #2 #4 #8 #16 #32 #64 #128 #256 Isolate
MP 0,0 0,0 12,5 75,0 75,0 87,5 100,0 OXA-58
IP 0,0 0,0 0,0 0,0 12,5 37,5 100,0 OXA-58
RI 0,0 0,0 0,0 75,0 75,0 75,0 100,0 OXA-58
AB 0,0 0,0 12,5 37,5 50,0 50,0 87,5 87,5 87,5 100,0 OXA-58
TGC 0,0 12,5 25,0 87,5 87,5 87,5 87,5 100,0 OXA-58
CO 100,0 OXA-58
MP 0,0 0,0 0,0 0,0 0,0 0,0 100,0 OXA-23
IP 0,0 0,0 0,0 0,0 0,0 3,0 100,0 OXA-23
RI 0,0 0,0 0,0 85,0 88,0 88,0 100,0 OXA-23
AB 0,0 0,0 0,0 6,0 12,0 74,0 89,0 95,0 95,0 100,0 OXA-23
TGC 0,0 6,0 12,0 94,0 97,0 100,0 OXA-23
CO 100,0 OXA-23
MP 0,0 0,0 0,0 0,0 0,0 0,0 100,0 OXA-24
IP 0,0 0,0 0,0 0,0 0,0 0,0 100,0 OXA-24
RI 0,0 0,0 0,0 100,0 OXA-24
AB 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 100,0 OXA-24
TGC 0,0 0,0 100,0 OXA-24
CO 100,0 OXA-24
MP 20,0 40,0 50,0 50,0 50,0 80,0 100,0 non OXA
IP 10,0 50,0 50,0 50,0 50,0 50,0 100,0 non OXA
RI 0,0 0,0 0,0 30,0 90,0 90,0 100,0 non OXA
AB 0,0 0,0 0,0 0,0 20,0 90,0 100,0 non OXA
TGC 0,0 0,0 0,0 70,0 100,0 non OXA
CO 100,0 non OXA
MP 75,0 100,0 Control
IP 100,0 Control
RI 0,0 25,0 50,0 50,0 75,0 100,0 Control
AB 0,0 75,0 75,0 75,0 75,0 75,0 75,0 75,0 100,0 Control
TGC 50,0 100,0 Control
CO 100,0 Control
MP, meropenem; IP, imipenem; RI, rifampicin; AB, ampicillin+sulbactam; TCG, tigecycline; CO, colistin.
doi:10.1371/journal.pone.0085854.t005
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